NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Price, News & Analysis $8.17 +0.08 (+0.99%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.81▼$8.5850-Day Range$6.56▼$9.4852-Week Range$6.38▼$29.70Volume297,127 shsAverage Volume322,203 shsMarket Capitalization$169.61 millionP/E RatioN/ADividend YieldN/APrice Target$35.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Adverum Biotechnologies alerts: Email Address Adverum Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside333.3% Upside$35.40 Price TargetShort InterestBearish9.37% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews Sentiment0.56Based on 5 Articles This WeekInsider TradingAcquiring Shares$1.05 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($5.50) to ($5.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.79 out of 5 starsMedical Sector40th out of 936 stocksBiological Products, Except Diagnostic Industry3rd out of 154 stocks 4.5 Analyst's Opinion Consensus RatingAdverum Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdverum Biotechnologies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adverum Biotechnologies' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.37% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adverum Biotechnologies has recently increased by 49.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Adverum Biotechnologies is -0.78. Previous Next 3.1 News and Social Media Coverage News SentimentAdverum Biotechnologies has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Adverum Biotechnologies this week, compared to 1 article on an average week.Search Interest6 people have searched for ADVM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,050,482.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adverum Biotechnologies' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Adverum Biotechnologies are expected to grow in the coming year, from ($5.50) to ($5.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adverum Biotechnologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Adverum Biotechnologies Stock (NASDAQ:ADVM)Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Read More ADVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADVM Stock News HeadlinesJuly 19, 2024 | insidertrades.comInsider Buying: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Buys 135,546 Shares of StockJuly 23 at 6:20 PM | markets.businessinsider.comStrong Phase 2 Results and Favorable Safety Profile Justify Buy Rating for Adverum BiotechnologiesJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 23 at 6:23 AM | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Lowered to Sell at StockNews.comJuly 19, 2024 | msn.comAdverum Releases Interim Data From Gene Therapy Study For Blindness Disorder, Prepares For Pivotal StudyJuly 19, 2024 | seekingalpha.comAdverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update TranscriptJuly 19, 2024 | msn.comAdverum posts mid-stage data for wet AMD candidateJuly 19, 2024 | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Price Target Raised to $40.00 at Chardan CapitalJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 19, 2024 | americanbankingnews.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Braden Michael Leonard Buys 135,546 Shares of StockJuly 17, 2024 | globenewswire.comAdverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual MeetingJuly 17, 2024 | americanbankingnews.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.20 Consensus Target Price from BrokeragesJuly 17, 2024 | americanbankingnews.comShort Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Drops By 5.8%May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adverum’s Gene Therapy on Promising Interim Phase 2 Results and Potential Standard of Care Shift in nAMD TreatmentMay 10, 2024 | finance.yahoo.comAdverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline ProgressMay 10, 2024 | investorplace.comADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024May 9, 2024 | chron.comAdverum Biotechnologies: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAdverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsSee More Headlines Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADVM CUSIPN/A CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees190Year FoundedN/APrice Target and Rating Average Stock Price Target$35.40 High Stock Price Target$60.00 Low Stock Price Target$22.00 Potential Upside/Downside+333.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($10.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,170,000.00 Net MarginsN/A Pretax Margin-3,284.53% Return on Equity-90.38% Return on Assets-51.37% Debt Debt-to-Equity RatioN/A Current Ratio9.24 Quick Ratio9.24 Sales & Book Value Annual Sales$3.60 million Price / Sales47.11 Cash FlowN/A Price / Cash FlowN/A Book Value$8.26 per share Price / Book0.99Miscellaneous Outstanding Shares20,760,000Free Float19,885,000Market Cap$169.61 million OptionableOptionable Beta1.07 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Laurent Fischer (Age 60)President, CEO & Director Comp: $1.02MMs. Linda M. Rubinstein M.A. (Age 57)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $940.99kMr. Kishor Peter Soparkar J.D. (Age 53)Chief Operating Officer Comp: $674.98kDr. Setareh Seyedkazemi Pharm.D. (Age 50)Chief Development Officer Comp: $656.84kDr. R. Andrew Ramelmeier Ph.D. (Age 62)Chief Technology Officer Dr. Romuald Corbau Ph.D. (Age 55)Chief Scientific Officer Mr. John W. Rakow J.D. (Age 67)Senior VP & General Counsel Comp: $954.24kMs. Dena HouseChief People OfficerMs. Carla FiankanSenior Vice President of Regulatory AffairsMr. Michael SteelSenior Vice President of QualityMore ExecutivesKey CompetitorsCoherus BioSciencesNASDAQ:CHRSSangamo TherapeuticsNASDAQ:SGMOCortexymeNASDAQ:CRTXBlack Diamond TherapeuticsNASDAQ:BDTXKalVista PharmaceuticalsNASDAQ:KALVView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 64,585 shares on 7/26/2024Ownership: 0.311%Assenagon Asset Management S.A.Bought 259,191 shares on 7/18/2024Ownership: 2.976%Braden Michael LeonardBought 135,546 shares on 7/17/2024Total: $1.05 M ($7.75/share)Avoro Capital Advisors LLCBought 416,666 shares on 5/15/2024Ownership: 2.007%Vanguard Group Inc.Sold 3,281,883 shares on 5/10/2024Ownership: 4.370%View All Insider TransactionsView All Institutional Transactions ADVM Stock Analysis - Frequently Asked Questions How have ADVM shares performed this year? Adverum Biotechnologies' stock was trading at $7.5280 at the start of the year. Since then, ADVM shares have increased by 8.5% and is now trading at $8.17. View the best growth stocks for 2024 here. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by $0.22. When did Adverum Biotechnologies' stock split? Adverum Biotechnologies's stock reverse split on the morning of Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO? 3 employees have rated Adverum Biotechnologies Chief Executive Officer Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among the company's employees. Who are Adverum Biotechnologies' major shareholders? Top institutional investors of Adverum Biotechnologies include Assenagon Asset Management S.A. (2.98%), Bank of New York Mellon Corp (0.31%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Braden Michael Leonard, Laurent Fischer, Peter Soparkar, Brigit Riley, James Paul Scopa, Setareh Seyedkazemi, Richard Beckman, Rupert D'souza and Julie Clark. View institutional ownership trends. How do I buy shares of Adverum Biotechnologies? Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX) and Immunomedics (IMMU). This page (NASDAQ:ADVM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
